PORT WASHINGTON, N.Y. – March 13, 2019: Pall Corporation, a global leader in filtration, separation and purification, announced the next step in the collaboration agreement with ARTeSYN Biosolutions, a leading innovator in single-use components and fluid management technologies. Under this co-exclusive agreement, the Pall Biotech line of business will immediately distribute ARTeSYN’s standard hardware and liner components off the shelf. ARTeSYN valves offer unmatched biopharmaceutical fluid flow control, with a compact, durable single-use design for simple installation and maintenance.

 

This co-distribution agreement with ARTeSYN Biosolutions is a critical element of our partnering program, and complements Pall’s existing Allegro™ integrated single-use portfolio of upstream, downstream and final filling solutions,” said Ed Hoare, Senior Vice President, Pall Biotech. “Customers will benefit from the flexibility, agility and reliability required for their bioprocessing journey. The agreement also helps to accelerate the implementation of robust and standardized single-use fluid management and controls, which has been an industry challenge for decades.”

 

“Adoption of single-use technology continues to grow within the cGMP clinical and commercial manufacturing space. This collaboration reflects our focus on accelerating single-use technology adoption for more efficient production of life saving drugs,” Michael Gagne, ARTeSYN Biosolutions founder and CXO commented. “We are excited to work with Pall, a company with which we share similar goals to offer innovative biotech solutions and an outstanding global commercial, technical and validation support network.”

 

The valves and fluid handling technologies are currently available to complement the Allegro™ single-use solutions portfolio. Learn more, or place an order.

 

 

About Pall Corporation

Pall Corporation is a filtration, separation and purification leader, providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.

For more information visit www.pall.com, or on YouTube, LinkedIn, Twitter, or Facebook.

 

About Artesyn Biosolutions

Artesyn Biosolutions, a privately held company, is a visionary brand in the area of single-use solutions for bioprocessing. ARTeSYN® has created a series of solutions targeting the voids and expanding the possibilities in the existing single-use space with the goal of enabling abundance in medicine. These solutions include patented and patent-pending valves, instruments, XO® skeletal supports, along with conventional unit operation systems like tangential flow filtration, chromatography, media and buffer prep in single-use formats that use these newly minted component solutions in their most advanced forms.

 

For more information, please visit www.artesynbiosolutions.com or follow us on Facebook, LinkedIn, Google+ or Twitter.

 

Corporate Media Contact

Pall Corporation

Mariann Kourafas
mariann_kourafas@pall.com

Director of Communications

+1-508-871-5469
 

Media Contact

White Matter Communications

Beth Willers

bethw@whitemattercomm.com

+1-415-905-0324

 

ARTeSYN Biosolutions Contact

Liis Oblikas

loblikas@artesynbio.com      

 

More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
July 2019
July 16, 2019: Servier chooses Pall as exclusive technology and services provider for planned Bio-S biomanufacturing facility in France
April 2019
April 29, 2019: Freeline's (AAV) manufacturing platform and Pall’s iCELLis bioreactor system combine to achieve commercial-scale and high quality production of AAV gene therapy vectors
March 2019
March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies
March 11, 2019: Pall Biotech to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors; sensor will be integrated into Pall Biotech’s single-use technologies
December 2018
December 18, 2018: New centre to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, and to provide technology solutions that meet current needs, while offering some of the most progressive technological solutions for the future
November 2018
November 26, 2018: Cobra and Pall to make commercialisation of gene therapies safer, faster, and cheaper than ever before, help increase patient access to gene therapy and further establish best practices in manufacturing
October 2018
October 2, 2018: New centre will work to enhance drug production and empower the future workforce, reinforcing Pall's commitment to continuously improve bioprocesses through strategic partnerships
September 2018
September 24, 2018: New collaboration to see G-CON PODs customized with Pall technologies, addressing customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing
September 11, 2018: Pall and Aetos partner to combine bioreactors, mixing and storage, and downstream technologies with cell lines and manufacturing processes for expedited biosimilars development
September 3, 2018: Celltheon and Pall to provide an integrated, cost-effective, time efficient end-to-end solution for research and bioproduction to expedite drug development and provide solutions for unmet needs in bioprocessing